【LBA4: Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2– advanced breast cancer (ABC): Phase 3, doub
讲者：梁旭
单位：北京大学肿瘤防治研 究所
【LBA109：Sacituzumab govitecan (SG)+pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 st
讲者：王涛
单位：解放军总医院
讲者：杨谨
单位：西安交通大学医学院第一附属医院
【5508：Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial】. 【
讲者：袁光文
单位：中国医学科学院肿瘤医院
讲者：杨宏英
单位：云南省肿瘤医院
【9512：Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage II/III acral melanoma: The CAP 03-NEO trial】. 【2502：Efficacy and safety results of a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 in patients (p
讲者：斯璐
单位：北京大学肿瘤医院
讲者：陈誉
单位：福建省肿瘤医院
【665：Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial】.【657：Nectin-4 targeted ADC
讲者：盛锡楠
讲者：魏强
单位：四川大学华西医院
【3001：Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations】
讲者：杨云鹏
单位：中山大学肿瘤防治中心
